114 related articles for article (PubMed ID: 22764566)
1. Exploratory computational assessment of possible binding modes for small molecule inhibitors of the CD40-CD154 co-stimulatory interaction.
Ganesan L; Vidović D; Schürer SC; Buchwald P
Pharmazie; 2012 May; 67(5):374-9. PubMed ID: 22764566
[TBL] [Abstract][Full Text] [Related]
2. Organic dyes as small molecule protein-protein interaction inhibitors for the CD40-CD154 costimulatory interaction.
Buchwald P; Margolles-Clark E; Kenyon NS; Ricordi C
J Mol Recognit; 2010; 23(1):65-73. PubMed ID: 19621420
[TBL] [Abstract][Full Text] [Related]
3. Effective and specific inhibition of the CD40-CD154 costimulatory interaction by a naphthalenesulphonic acid derivative.
Margolles-Clark E; Kenyon NS; Ricordi C; Buchwald P
Chem Biol Drug Des; 2010 Oct; 76(4):305-13. PubMed ID: 20636329
[TBL] [Abstract][Full Text] [Related]
4. Small molecule inhibition of the TNF family cytokine CD40 ligand through a subunit fracture mechanism.
Silvian LF; Friedman JE; Strauch K; Cachero TG; Day ES; Qian F; Cunningham B; Fung A; Sun L; Shipps GW; Su L; Zheng Z; Kumaravel G; Whitty A
ACS Chem Biol; 2011 Jun; 6(6):636-47. PubMed ID: 21417339
[TBL] [Abstract][Full Text] [Related]
5. The CD40-CD154 co-stimulation pathway mediates innate immune injury in adriamycin nephrosis.
Lee VW; Qin X; Wang Y; Zheng G; Wang Y; Wang Y; Ince J; Tan TK; Kairaitis LK; Alexander SI; Harris DC
Nephrol Dial Transplant; 2010 Mar; 25(3):717-30. PubMed ID: 19889873
[TBL] [Abstract][Full Text] [Related]
6. Prospects for CD40-directed experimental therapy of human cancer.
Tong AW; Stone MJ
Cancer Gene Ther; 2003 Jan; 10(1):1-13. PubMed ID: 12489023
[TBL] [Abstract][Full Text] [Related]
7. Tuning of CD40-CD154 interactions in human B-lymphocyte activation: a broad array of in vitro models for a complex in vivo situation.
Néron S; Nadeau PJ; Darveau A; Leblanc JF
Arch Immunol Ther Exp (Warsz); 2011 Feb; 59(1):25-40. PubMed ID: 21234809
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive identification of "druggable" protein ligand binding sites.
An J; Totrov M; Abagyan R
Genome Inform; 2004; 15(2):31-41. PubMed ID: 15706489
[TBL] [Abstract][Full Text] [Related]
9. Determination of carbohydrate structures N-linked to soluble CD154 and characterization of the interactions of CD40 with CD154 expressed in Pichia pastoris and Chinese hamster ovary cells.
Khandekar SS; Silverman C; Wells-Marani J; Bacon AM; Birrell H; Brigham-Burke M; DeMarini DJ; Jonak ZL; Camilleri P; Fishman-Lobell J
Protein Expr Purif; 2001 Nov; 23(2):301-10. PubMed ID: 11676606
[TBL] [Abstract][Full Text] [Related]
10. CD154-CD40 interactions are essential for thymus-dependent antibody production in zebrafish: insights into the origin of costimulatory pathway in helper T cell-regulated adaptive immunity in early vertebrates.
Gong YF; Xiang LX; Shao JZ
J Immunol; 2009 Jun; 182(12):7749-62. PubMed ID: 19494299
[TBL] [Abstract][Full Text] [Related]
11. Domain-based small molecule binding site annotation.
Snyder KA; Feldman HJ; Dumontier M; Salama JJ; Hogue CW
BMC Bioinformatics; 2006 Mar; 7():152. PubMed ID: 16545112
[TBL] [Abstract][Full Text] [Related]
12. Characterization of RNA binding proteins associated with CD40 ligand (CD154) mRNA turnover in human T lymphocytes.
Rigby WF; Waugh MG; Hamilton BJ
J Immunol; 1999 Oct; 163(8):4199-206. PubMed ID: 10510356
[TBL] [Abstract][Full Text] [Related]
13. Discovery of small molecule CD40-TRAF6 inhibitors.
Zarzycka B; Seijkens T; Nabuurs SB; Ritschel T; Grommes J; Soehnlein O; Schrijver R; van Tiel CM; Hackeng TM; Weber C; Giehler F; Kieser A; Lutgens E; Vriend G; Nicolaes GA
J Chem Inf Model; 2015 Feb; 55(2):294-307. PubMed ID: 25622654
[TBL] [Abstract][Full Text] [Related]
14. CD154 and its receptors in inflammatory vascular pathologies.
Hassan GS; Merhi Y; Mourad WM
Trends Immunol; 2009 Apr; 30(4):165-72. PubMed ID: 19282242
[TBL] [Abstract][Full Text] [Related]
15. Small-molecule protein-protein interaction inhibitors: therapeutic potential in light of molecular size, chemical space, and ligand binding efficiency considerations.
Buchwald P
IUBMB Life; 2010 Oct; 62(10):724-31. PubMed ID: 20979208
[TBL] [Abstract][Full Text] [Related]
16. CD154/CD40-mediated expression of CD154 in endothelial cells: consequences for endothelial cell-monocyte interaction.
Wagner AH; Güldenzoph B; Lienenlüke B; Hecker M
Arterioscler Thromb Vasc Biol; 2004 Apr; 24(4):715-20. PubMed ID: 14976003
[TBL] [Abstract][Full Text] [Related]
17. A pharmacophore docking algorithm and its application to the cross-docking of 18 HIV-NNRTI's in their binding pockets.
Daeyaert F; de Jonge M; Heeres J; Koymans L; Lewi P; Vinkers MH; Janssen PA
Proteins; 2004 Feb; 54(3):526-33. PubMed ID: 14748000
[TBL] [Abstract][Full Text] [Related]
18. Up-regulation of CD40 with juxtacrine activity in human nonsmall lung cancer cells correlates with poor prognosis.
Ishikawa K; Miyamoto M; Yoshioka T; Kato T; Kaji M; Ohbuchi T; Hirano S; Itoh T; Dosaka-Akita H; Kondo S
Cancer; 2008 Aug; 113(3):530-41. PubMed ID: 18548529
[TBL] [Abstract][Full Text] [Related]
19. A CD40-CD154 interaction in tissue fibrosis.
Kawai M; Masuda A; Kuwana M
Arthritis Rheum; 2008 Nov; 58(11):3562-73. PubMed ID: 18975310
[TBL] [Abstract][Full Text] [Related]
20. Estimation of the number of CD154 molecules in membrane extracts used as a source of CD40 stimulation of human B lymphocytes.
Ducas E; Dussault N; Roy A; Dumont N; Néron S
J Immunol Methods; 2009 May; 344(2):133-7. PubMed ID: 19332074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
